Over 1,000 U.S. cases have now been performed with OMNIlife science’s OMNIBotics® Active Spacer.
The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. It is reportedly the only available system that supports predictive balance of ligaments through dynamic, real-time feedback across the entire range of motion, that can deliver computer calculated, robotic-assisted bone cutting.
The OMNIBotics system for TKR is driven by OMNI’s proprietary ART™ software, and has been used to perform >17,000 procedures to date worldwide.
Over 1,000 U.S. cases have now been performed with OMNIlife science’s OMNIBotics® Active Spacer.
The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. It is reportedly the only available system that supports predictive balance of ligaments through dynamic, real-time...
Over 1,000 U.S. cases have now been performed with OMNIlife science’s OMNIBotics® Active Spacer.
The Active Spacer entered clinical use in Australia at the end of 1Q17, and received FDA 510(k) clearance at the end of 3Q17. It is reportedly the only available system that supports predictive balance of ligaments through dynamic, real-time feedback across the entire range of motion, that can deliver computer calculated, robotic-assisted bone cutting.
The OMNIBotics system for TKR is driven by OMNI’s proprietary ART™ software, and has been used to perform >17,000 procedures to date worldwide.
Copy to clipboard 
